O-GlcNAcase patented technology retrieval search results - Eureka

Q: How to O-GlcNAcase?

Selective glycosidase inhibitors and uses thereof,Selective glycosidase inhibitors and uses thereof,Selective glycosidase inhibitors and uses thereof,Selective Glycosidase Inhibitors and Uses Thereof,Selective glycosidase inhibitors and uses thereof

Selective glycosidase inhibitors and uses thereof

ActiveUS20100016386A1Improve the level ofOrganic active ingredientsBiocideDiseaseGlycosidase inhibitor

The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc

Selective glycosidase inhibitors and uses thereof

View all

Owner:SIMON FRASER UNIVERSITY

Selective glycosidase inhibitors and uses thereof

InactiveCN101595111AOrganic active ingredientsSugar derivativesDisaccharidaseGlycosidase inhibitor

The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

View all

Owner:SIMON FRASER UNIVERSITY

Selective glycosidase inhibitors and uses thereof

InactiveUS9120781B2BiocideNervous disorderDisaccharidaseDisease

The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

View all

Owner:SIMON FRASER UNIVERSITY +2

Selective Glycosidase Inhibitors and Uses Thereof

InactiveUS20110237631A1Improve the level ofBiocideNervous disorderDiseaseDisaccharidase

The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcN Ac.

View all

Owner:SIMON FRASER UNIVERSITY

Selective glycosidase inhibitors and uses thereof

InactiveUS20120316207A1BiocideOrganic active ingredientsDiseaseGlycosidase inhibitor

The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

View all

Owner:SIMON FRASER UNIVERSITY

Selective glycosidase inhibitors and uses thereof

InactiveUS20140005191A1Improve the level ofEsterified saccharide compoundsCompound screeningGlycosidase inhibitorO-GlcNAcase

The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

View all

Owner:ALECTOS THERAPEUTICS +1

Selective Glycosidase Inhibitors and Uses Thereof

InactiveUS20110301217A1BiocideCompound screeningDisaccharidaseGlycosidase inhibitor

The application relates to an immoalditol compound for selectively inhibiting glycosidases, a prodrug thereof and a pharmaceutical composition comprising the compound or the prodrug The application also relates to the use of the immoalditol compound for treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc Such diseases and disorders include neurodegenerative diseases, tauopathy, cancers, and cardiac disorders

View all

Owner:SIMON FRASER UNIVERSITY

Selective glycosidase inhibitors and uses thereof

InactiveUS8541441B2BiocideCompound screeningGlycosidase inhibitorO-GlcNAcase

The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

View all

Owner:SIMON FRASER UNIVERSITY

Selective glycosidase inhibitors and uses thereof

InactiveUS20140088028A1Esterified saccharide compoundsBiocideDiseaseGlycosidase inhibitor

The invention provides compounds of formula (I) with substituents as specified in Claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to over-expression of O-GlcNAcase or accumulation of O-GlcNac.

View all

Owner:MERCK SHARP & DOHME CORP +1

Selective glycosidase inhibitors and uses thereof

ActiveUS20130131044A1Improve the level ofBiocideNervous disorderGlycosidase inhibitorO-GlcNAcase

The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

View all

Owner:SIMON FRASER UNIVERSITY +2

Selective glycosidase inhibitors and uses thereof

InactiveUS20140107044A1Esterified saccharide compoundsBiocideGlycosidase inhibitorO-GlcNAcase

The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

View all

Owner:MERCK SHARP & DOHME CORP +1

Selective glycosidase inhibitors and uses thereof

ActiveUS20140018309A1Improve breathabilityCompound screeningBiocideGlycosidase inhibitorO-GlcNAcase

The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

View all

Owner:ALECTOS THERAPEUTICS

Selective glycosidase inhibitors and uses thereof

InactiveUS20140275022A1BiocideOrganic active ingredientsGlycosidase inhibitorO-GlcNAcase

The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

View all

Owner:MERCK SHARP & DOHME CORP +1

Selective glycosidase inhibitors and uses thereof

ActiveUS20140296205A1Improve breathabilityOrganic active ingredientsSenses disorderGlycosidase inhibitorO-GlcNAcase

The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

View all

Owner:ALECTOS THERAPEUTICS

Selective glycosidase inhibitors

InactiveUS20100087477A1BiocideNervous disorderDiseaseGlycosidase inhibitor

The present invention provides glucoimidazole derivatives and methods of making them. The compounds can be used to inhibit the activity of O-GlcNAcase enzymes, including both bacterial OGA (bOGA) and human OGA (hOGA) and can be selective, showing low inhibition of hexosaminidases. The compounds can be used to study the role of the O-GlcNAcase modification in human or animal cells. Furthermore the compounds can have therapeutic uses in the treatment of diseases mediated by the activity of O-GlcNAcase enzymes including type II diabetes, Alzheimers disease, and cancer.

View all

Owner:UNIV COURT OF THE UNIV OF DUNDEE

Selective glycosidase inhibitors and uses thereof

InactiveUS8927507B2Esterified saccharide compoundsBiocideGlycosidase inhibitorO-GlcNAcase

The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

View all

Owner:MERCK SHARP & DOHME CORP +1

Selective glycosidase inhibitors and uses thereof

ActiveUS20150045346A1Improve breathabilityBiocideCompound screeningGlycosidase inhibitorO-GlcNAcase

The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

View all

Owner:ALECTOS THERAPEUTICS INC

Permeable glycosidase inhibitors and uses thereof

ActiveUS20150152127A1Isotope introduction to sugar derivativesBiocideN acetylglucosaminidaseGlycosidase inhibitor

The present invention is directed to compounds and pharmaceutical formulations comprising these compounds which are useful as O-linked N-acetylglucosaminidase (O-GlcNAcase) inhibitors, and thus may be useful for the treatment of certain disorders such as Alzheimer's disease including reducing NFTs and / or hyperphosphorylated tau. The invention is also directed to use of the compounds as O-GlcNAcase imaging agents.

Permeable glycosidase inhibitors and uses thereof

View all

Owner:ALECTOS THERAPEUTICS

Selective glycosidase inhibitors and uses thereof

ActiveUS9243020B2Improve breathabilityCompound screeningSenses disorderGlycosidase inhibitorO-GlcNAcase

The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

View all

Owner:ALECTOS THERAPEUTICS INC

Selective Glycosidase Inhibitors and Uses Thereof

InactiveUS20120095033A1BiocideCompound screeningGlycosidase inhibitorO-GlcNAcase

The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

View all

Owner:SIMON FRASER UNIVERSITY

Glycosidase inhibitors and uses thereof

InactiveUS20150218147A1Improve breathabilityHigh selectivityBiocideNervous disorderDiseaseGlycosidase inhibitor

The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

View all

Owner:MERCK SHARP & DOHME CORP +1

Glycosidase inhibitors and uses thereof

ActiveUS9938299B2Improve breathabilityNervous disorderOrganic chemistryGlycosidase inhibitorO-GlcNAcase

The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

View all

Owner:ALECTOS THERAPEUTICS

Selective glycosidase inhibitors and uses thereof

ActiveUS9409924B2Improve breathabilityOrganic active ingredientsCompound screeningGlycosidase inhibitorO-GlcNAcase

The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

View all

Owner:ALECTOS THERAPEUTICS INC

Selective glycosidase inhibitors and uses thereof

InactiveCN107253970AOrganic active ingredientsNervous disorderDiseaseDisaccharidase

The invention relates to s elective glycosidase inhibitors and uses thereof and provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

View all

Owner:SIMON FRASER UNIVERSITY

Quantitative detection method of O-GlcNAc

InactiveCN106645038AEasy to operateAvoid interferencePhase-affecting property measurementsDisease diagnosisEnzyme digestionCancer cell

The invention discloses a quantitative detection method of O-GlcNAc, comprising the following steps: detecting O-GlcNAc according to SPR signals recorded according to change of the refractive index caused by the inter combination effect of wheat germ agglutinin WGA and O-GlcNAc on a gold film; cutting O-GlcNAcase (OGA) by using the specificity of O-GlcNAc, wherein signal decrease after cutting is related to the concentration of O-GlcNAc; and according to change of signal delta R before and after enzyme digestion, realizing accurate and quantitative detection of O-GlcNAc. The quantitative detection method of O-GlcNAc has low requirements on samples which can be detected after simple treatment, is simple in operation, has a wide linear range relative to the previously reported work, and can be applied to detection of O-GlcNAc in cancer cells.

View all

Owner:UNIVERSITY OF CHINESE ACADEMY OF SCIENCES

O-GlcNAcase-specific inhibitor and substrate engineered by the extension of the N-Acetyl moiety

InactiveUS20080182805A1BiocideSugar derivativesD-GlucopyranoseFluorescence

An O-GlcNAcase-specific inhibitor and substrate are engineered by the extension of the N-Acetyl Moiety of O-(2-acet-amido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate (PUGNAc). The reagent substrate includes a fluorophor and the inhibitor. This reagent substrate is for high-throughput analysis of O-GlcNAcase within cellular assays and imaging agent for the in vivo analysis of O-GlcNAcase.